Drugs / canfosfamide

Trials 15 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/25 trials
Phase 1/2 NCT00088556 Aug 2004 → May 2009 non-small cell lung carcinoma Telik Completed No outcome recorded
Phase 1/2 NCT00077883 Feb 2004 → Mar 2007 non-small cell lung carcinoma Telik Completed No outcome recorded
Phase 1/2 NCT00052065 Feb 2003 → Mar 2006 ovarian neoplasm Telik Completed No outcome recorded
Phase 1/2 NCT00051948 Jan 2003 → Jan 2005 ovarian cancer Telik Completed No outcome recorded
Phase 1/2 NCT00047801 Oct 2002 → Sep 2004 non-small cell lung carcinoma Telik Completed No outcome recorded
Phase 26 trials
Phase 2 NCT01148108 Jun 2010 → Sep 2012 mantle cell lymphoma, plasma cell myeloma Telik Completed No outcome recorded
Phase 2 NCT00040638 Jul 2002 → Aug 2003 non-small cell lung carcinoma Telik Completed No outcome recorded
Phase 2 NCT00035841 Apr 2002 → Jul 2004 breast cancer Telik Completed No outcome recorded
Phase 2 NCT00036920 Jan → Aug 2002 lung cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 2 NCT00038428 Jun 2001 → Jul 2005 ovarian neoplasm Telik Completed No outcome recorded
Phase 2 NCT00022347 May 2001 → Apr 2004 fallopian tube cancer, ovarian cancer, peritoneum cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 34 trials
Phase 3 NCT00350948 May 2006 → Dec 2008 ovarian neoplasm Telik Terminated No outcome recorded
Phase 3 NCT00102973 Dec 2004 → Jul 2008 ovarian neoplasm Telik Completed No outcome recorded
Phase 3 NCT00057720 Jun 2003 → Dec 2006 ovarian neoplasm Telik Completed No outcome recorded
Phase 3 NCT00080340 ? → May 2005 non-small cell lung carcinoma Telik Completed No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as canfosfamide Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1.” PMID 20222977 Mar 2010
3

NCT00036920

NCT01148108

NCT00022347

Known as Canfosfamida ChEMBL registry synonym — accepted as the source's own label CHEMBL2111086
Known as canfosfamide HCl “30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks” NCT01148108
Known as CANFOSFAMIDE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2111086
Known as Canfosfamidhydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL2111086
Known as Telcyta “TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer” NCT00102973
3

“TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer” NCT00057720

“TLK286 (Telcyta) HCl for Injection” NCT00080340

NCT00350948

Known as TELCYTA(TM) “The purpose of this study was to determine the safety and efficacy of TLK286 (TELCYTA(TM)), a glutathione analog prodrug, in patients with platinum and paclitaxel refractory or...” PMID 16014111 Jul 2005
Known as TER-286 ChEMBL registry synonym — accepted as the source's own label CHEMBL2111086
Known as TLK286 “The purpose of this study was to determine the safety and efficacy of TLK286 (TELCYTA(TM)), a glutathione analog prodrug, in patients with platinum and paclitaxel refractory or...” PMID 16014111 Jul 2005
10

NCT00051948

NCT00047801

NCT00040638

NCT00077883

NCT00102973

NCT00057720

NCT00035841

NCT00038428

NCT00088556

NCT00080340

Known as TLK286 HCl TLK286 HCl for injection” NCT00057720
Modality Small molecule “a glutathione analog prodrug” PMID 16014111 Jul 2005
1

CHEMBL2111086

Route Intravenous “TLK286 IV over 30 minutes” NCT00022347